Decoy Therapeutics (NASDAQ:DCOY) Shares Up 3.9% – Should You Buy?

Decoy Therapeutics (NASDAQ:DCOY)’s stock price shot up 3.9% on Monday . The company traded as high as $6.70 and last traded at $6.07. 11,509 shares traded hands during mid-day trading, a decline of 63% from the average session volume of 31,158 shares. The stock had previously closed at $5.84.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. LADENBURG THALM/SH SH assumed coverage on shares of Decoy Therapeutics in a research note on Friday, January 23rd. They issued a “buy” rating and a $30.00 price target on the stock. Weiss Ratings assumed coverage on shares of Decoy Therapeutics in a research note on Thursday, January 22nd. They issued a “sell (e)” rating on the stock. Finally, Wall Street Zen upgraded shares of Decoy Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 21st. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $30.00.

Decoy Therapeutics Stock Performance

The stock’s 50 day moving average price is $7.68. The company has a market cap of $3.22 million, a price-to-earnings ratio of -0.01 and a beta of 0.37.

Decoy Therapeutics (NASDAQ:DCOY) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $43.10 earnings per share (EPS) for the quarter.

About Decoy Therapeutics

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.